Experimental Toxicology (human iPSC-based platform)
Human induced pluripotent stem cells
Experimental Toxicology (human iPSC-based platform)
iCardio - Toxicology platform
iCardio - Toxicology platform
iCardio-Toxicology Platform
Testing cardio - toxicity using iPSCs
Aryastha Biosolutions® for in vitro Human iPSC-based Cardiac modeling
Morphology and Immunostaining
- A1AT, Albumin, CK18, GSTA1
Gene Expression
- qRT-PCR analysis for hepatocyte marker expression:
- Albumin (a hepatocyte maturation marker), CYP3A4/5/7, CYP2C9/19, CYP2D6, CYP2B6
- HNF4a (Hepatocyte Nuclear Factor 4 Alpha), AFP (Alpha-Fetoprotein), PXR (Pregnane X Receptor)
- Key cytochrome P450 genes (CYP1A, CYP3A, CYP2C9)
- Functional transcriptomics and proteomics - RNA seq, LC/MS
Functional characterization (using ELISA, LC/MS, WB, Colorimetric assays)
- Albumin secretion
- Urea production
- Glycogen storage
- LDL uptake
- Bile synthesis and secretion assays
Team Expertise and Strength
- Developing iPSC disease models for :
- Tauopathies (FTD/AD)
- Neurodegeneration (ALS, Schizophrenia, Rett syndrome)
- Pulmonary disorders (SCLC, NEHI)
- Oncology and solid tumors (Leukemia/Lymphoma, Ovarian cancer, Breast cancer, Lung adenocarcinoma)
- Establishing human iPSC-based cellular reprogramming strategies to generate induced cell types of :
- Neuronal origin
- Glial origin
- Pulmonary origin
- Hemato-lymphoid origin
- Establishing drug discovery platforms for high-throughput screening (HTS) using co-culture assays with induced cell types
